Fig. 10

CHK1 inhibitors synergic effects with 4OH-Tamoxifen in MCF-7 cells. Kaplan–Meier plots showing the relapse-free survival (RFS) probability in women carrying breast tumors expressing either ERα, progesterone receptor (PR) but not HER2 (A) or ERα, but not PR or both expressing or not HER2 (B) as a function of CHK1 mRNA levels. All possible cutoff values between the lower and upper quartiles are automatically computed (i.e., auto select best cutoff on the website), and the best performing threshold is used as a cutoff [27]. Details of the parameters of the curves are given in supplementary table 3. Significant differences between the RFS are given as p-value in each panel. Synergy map of 12 days-treated MCF-7 (C) and T47D-1 (D) cells with different doses of 4OH-Tamoxifen (Tam) and AZD7762 (AZD) or prexasertib (Prexa) (C, and D left and right panels, respectively). Growth curves in MCF-7 (C’) or T47D-1 (D’) cells show the synergic effect of each combination of compounds with selected doses. Significant differences with respect to untreated (i.e., -,-) samples are calculated by Student t-test and indicated by **** p-value < 0.0001. Significant differences between Tam + AZD with respect to Tam alone or AZD alone are calculated by Student t-test and indicated by ° p-value < 0.05. Significant differences between Tam + Prexa with respect to Tam alone or Prexa alone are calculated by Student t-test and indicated by ^ p-value < 0.05. For details, please see the material and methods section